Benta has announced the acquisition of NerPharMa, a pharmaceutical manufacturing company located in Milan, Italy, from NMS Group. The acquisition marks a significant step in strengthening Benta’s European industrial platform and expanding its specialized oncology, biologics and high potency manufacturing capabilities.
Strategically located in one of Europe’s leading pharmaceutical hubs, NerPharMa operates a facility accredited by multiple regulatory authorities, including the EMA and the US FDA, and employs over 100 staff members. The site provides comprehensive manufacturing capabilities across biologics and high potency integrated drug product (DP), as well as drug substance (DS) services in oral solid dosages and injectables.
NerPharMa supports a diverse portfolio of active clients, ranging from local businesses to multinational corporations. This acquisition represents a significant step forward in expanding Benta’s European operations. It will enable us to enhance our capabilities in complex therapies, such as biologics and high potency products, while strengthening our international client network. Benta is now positioning well as one stop shop CMO partner in all galenic forms from process chemistry to distribution ” said Bernard Tannoury, Chairman & CEO of Benta.
This divestment marks a pivotal development in our transition towards becoming an an organization dedicated to oncology innovation,” stated Dr. Hugues Dolgos, PharmD, CEO of NMS Group. “By focusing our efforts on small molecule and ADCs research and development, we are better positioned to expedite the advancement of the delivery of breakthrought treatments. I am confident that NerPharMa will continue to progress as part of Benta’s global network.